Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122672) titled 'Study on the Efficacy and Safety of telitacicept in the Treatment of Systemic lupus Erythematosus complicated with Immune Cirrhosis' on April 16.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Nanchang University
Condition:
Systemic lupus erythematosus complicated with immune liver cirrhosis
Intervention:
Teprotumumab Treatment Group:Subcutaneous injection of Teprotumumab 160mg once weekly (dose can be reduced to 80mg/week after disease stabilization)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-29
Targe...